Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)
A phase 2 trial of Artesunate ointment in vulvar cancer, run by Frantz Viral Therapeutics, LLC, now recruiting.
Overview
Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3) is a phase 2 interventional study registered as NCT06075264 by Frantz Viral Therapeutics, LLC, with 27 participants planned, started 2023-12-06 and due to reach its primary completion in 2026-12. Interventions recorded: Artesunate ointment and Placebo ointment.
Setting
A Phase II Double-blind, Placebo-controlled, Randomized Trial of Topical Artesunate Ointment for the Treatment of Patients With Vulvar High-grade Squamous Intraepithelial Lesions (Vulvar HSIL)
Phase
Phase 2
Sponsor
Frantz Viral Therapeutics, LLC
Registry
Enrolled
27
Similar pages
not linked directly; found by shared links- TreatmentLorigerlimab
Shares Vulvar cancer and the tag pipeline.